Air purification company Aerus stated on Wednesday that its ActivePure Technology with Hydroxyl Blaster established a 99.98% surface kill rate of live SARS-CoV-2 virus in seven hours based on the testing data conducted by independent FDA compliant laboratory, MRIGlobal.
The company's ActivePure Technology is scientifically proven to destroy microscopic pathogens and contaminants on surfaces and in the air and is available in over 70 Aerus products, including the Aerus Medical Guardian cleared by the FDA as a Class II Medical Device 510(k).
According to the company, the Aerus Hydroxyl Blaster with ActivePure Technology is an affordable, mobile, plug-and-purify air purifier that works on interior aerosolized pathogens and surface contaminants.
In conjunction, the company is awaiting final approval from the US FDA for Emergency Use Authorization (EUA) for the Aerus Hydroxyl Blaster with ActivePure Technology for use in reducing SARS-CoV-2 surface pathogens. The results have a been submitted to the FDA-equivalent Canadian and European Union regulators as well. It expects to receive clearances in all jurisdictions.
Concurrently, the company is running independent laboratory tests to demonstrate the efficacy of ActivePure Technology on airborne SARS-CoV-2 virus for US FDA clearance.
Sanofi's Nexviadyme gets EU approval in Pompe disease
Ceruvia Lifesciences' synthetic psilocybin Phase two clinical trial receives US FDA approval
Ipsen agrees to acquire Epizyme
ImmuPharma reports Avion seeking final FDA guidance ahead of Phase 3 trial of Lupuzor
Daewoong Pharmaceutical's IND for DWN12088 receives FDA approval for phase two clinical trial
Investigational Lenacapavir Receives Positive CHMP Opinion for People with Multi-Drug Resistant HIV